Literature DB >> 26322453

Surgical resection of cervical schwannoma and paraganglioma: Speech and swallowing outcomes.

Noah P Parker1, Noel Jabbour, Amy Anne Lassig, Bevan Yueh, Samir S Khariwala.   

Abstract

We conducted a retrospective study (1999 to 2009) at our tertiary care institution to evaluate speech and swallowing outcomes after the resection of cervical schwannoma or paraganglioma. Of 6 patients treated for schwannoma, 5 (83.3%) had immediate dysphonia and dysphagia. All patients with deficits received primary reinnervation (n = 2) or subsequent medialization laryngoplasty (n = 3). At 6 months, 4 patients (66.6%) still had dysphonia and dysphagia. At final follow-up (median: 10 months; range: 8 to 12 months), 4 patients (66.7%) had dysphonia and 2 (33.3%) had dysphagia. Of 10 patients treated for paraganglioma, 6 (60.0%) had immediate dysphonia and dysphagia. Four patients received subsequent medialization laryngoplasty; none had primary reinnervation. At 6 months, 3 (30%) still had dysphonia and dysphagia. At final follow-up (median: 15.5 months; range: 1.25 to 48 months), 2 (20.0%) had dysphonia and dysphagia. All patients with deficits received speech and swallowing therapy. We conclude that cervical schwannoma and paraganglioma resection was associated with high rates of immediate postoperative dysphonia and dysphagia. Schwannoma had higher initial rates and poorer recovery. Primary and/or subsequent laryngeal procedures combined with therapy led to symptom resolution in some patients.

Entities:  

Mesh:

Year:  2015        PMID: 26322453      PMCID: PMC4890561     

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  13 in total

1.  Brief report: Advanced paraganglioma: A role for chemotherapy?

Authors:  O Fitoussi; M Debled; B Masson; J M Coindre; G Kantor; B N Bui
Journal:  Med Pediatr Oncol       Date:  1999-08

2.  (ELECTRON MICROSCOPIC OBSERVATIONS ON THE STRUCTURE OF THE RAT ADRENAL MEDULLA. I. THE ULTRASTRUCTURE AND ORGANIZATION OF CHROMAFFIN CELLS IN THE NORMAL ADRENAL MEDULLA.)

Authors:  R E COUPLAND
Journal:  J Anat       Date:  1965-04       Impact factor: 2.610

Review 3.  Clinical results: Radiosurgery and radiotherapy of cranial nerve schwannomas.

Authors:  John C Flickinger; Fred G Barker
Journal:  Neurosurg Clin N Am       Date:  2006-04       Impact factor: 2.509

4.  Radiotherapy in the management of temporal bone chemodectoma.

Authors:  W M Mendenhall; J T Parsons; S P Stringer; N J Cassisi; G T Singleton; R R Million
Journal:  Skull Base Surg       Date:  1995

5.  Head and neck schwannomas--a 10 year review.

Authors:  M P Colreavy; P D Lacy; J Hughes; D Bouchier-Hayes; P Brennan; A J O'Dwyer; M J Donnelly; R Gaffney; A Maguire; T P O'Dwyer; C V Timon; M A Walsh
Journal:  J Laryngol Otol       Date:  2000-02       Impact factor: 1.469

Review 6.  Treatment of paragangliomas with radiation therapy.

Authors:  W M Mendenhall; R W Hinerman; R J Amdur; S P Stringer; P J Antonelli; G T Singleton; N J Cassisi
Journal:  Otolaryngol Clin North Am       Date:  2001-10       Impact factor: 3.346

Review 7.  Vagal paragangliomas.

Authors:  J C Sniezek; J L Netterville; A N Sabri
Journal:  Otolaryngol Clin North Am       Date:  2001-10       Impact factor: 3.346

8.  Radiotherapy in the management of chemodectomas of the carotid body and glomus vagale.

Authors:  L J Evenson; W M Mendenhall; J T Parsons; N J Cassisi
Journal:  Head Neck       Date:  1998-10       Impact factor: 3.147

Review 9.  Paragangliomas of the head and neck.

Authors:  Phillip K Pellitteri; Alessandra Rinaldo; David Myssiorek; C Gary Jackson; Patrick J Bradley; Kenneth O Devaney; Ashok R Shaha; James L Netterville; Johannes J Manni; Alfio Ferlito
Journal:  Oral Oncol       Date:  2004-07       Impact factor: 5.337

Review 10.  Expected neurologic outcomes for surgical treatment of cervical neurilemomas.

Authors:  J Valentino; M A Boggess; J L Ellis; T O Hester; R O Jones
Journal:  Laryngoscope       Date:  1998-07       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.